DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned a consensus rating of “Moderate Buy” from the eighteen analysts that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $98.00.

A number of brokerages have issued reports on DXCM. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Citigroup raised their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Leerink Partners decreased their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th.

DexCom Trading Down 0.7 %

Shares of DXCM opened at $79.35 on Wednesday. DexCom has a one year low of $62.34 and a one year high of $142.00. The stock has a 50-day moving average price of $76.28 and a 200 day moving average price of $79.78. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market capitalization of $30.99 billion, a P/E ratio of 47.52, a P/E/G ratio of 2.46 and a beta of 1.12.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter worth $25,000. Sachetta LLC lifted its position in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares in the last quarter. Riverview Trust Co boosted its stake in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd raised its stake in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the period. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.